series-a
Stage
1
Investors
About
Creyon Bio develops tissue-specific RNA-targeted nucleic acid therapies using proprietary aptamer delivery technology and AI-driven design tools to treat immunology, central nervous system, and neuromuscular diseases.
Explore Creyon Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.